摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-三丁基甲锡烷基噻吩 | 54663-78-4

中文名称
2-三丁基甲锡烷基噻吩
中文别名
2-(三-N-丁基甲锡烷基)噻吩;三丁基(2-噻吩基)锡;2-(三丁基锡)噻吩
英文名称
tributyl(thien-2-yl)stannane
英文别名
2-(tributylstannyl)thiophene;tributyl(thiophen-2-yl)stannane;2-tri(n-butyl)stannylthiophene;tributyl(2-thienyl)stannane;2-(tributyltin)thiophene;tributyl(thiophene-2-yl)stannane;2-thienyltributylstannane;2-tri-n-butyltinthiophene;2-thienyl(tributyl)tin;tributyl(2-thienyl)tin;tri-n-butyl(thiophen-2-yl)stannane;tri(n-butyl)-2-thienylstannane;2-(tributylstanny)thiophene;(thiophen-2-yl)tributyltin;tributylstannylthiophene;2-thiophenyl(tributyl)stannane;2-(tributylstannyl)thiofuran;tri-n-butylstannylthiophene
2-三丁基甲锡烷基噻吩化学式
CAS
54663-78-4
化学式
C16H30SSn
mdl
——
分子量
373.19
InChiKey
UKTDFYOZPFNQOQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    197-198 °C
  • 沸点:
    155 °C/0.1 mmHg (lit.)
  • 密度:
    1.175 g/mL at 25 °C (lit.)
  • 闪点:
    221 °F
  • 稳定性/保质期:
    如果按照规格正确使用和储存,则不会发生分解,也未发现有已知的危险反应。

计算性质

  • 辛醇/水分配系数(LogP):
    5.8
  • 重原子数:
    18
  • 可旋转键数:
    10
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.75
  • 拓扑面积:
    28.2
  • 氢给体数:
    0
  • 氢受体数:
    1

安全信息

  • TSCA:
    No
  • 危险等级:
    6.1(b)
  • 危险品标志:
    T,N
  • 安全说明:
    S35,S36/37/39,S45,S60,S61
  • 危险类别码:
    R48/23/25,R36/38,R21,R50/53,R25
  • WGK Germany:
    3
  • 海关编码:
    2934999090
  • 危险品运输编号:
    UN 2788 6.1/PG 3
  • 危险类别:
    6.1(b)
  • 包装等级:
    III
  • 危险标志:
    GHS06,GHS08,GHS09
  • 危险性描述:
    H301,H312,H315,H319,H372,H410
  • 危险性防范说明:
    P260,P280,P305 + P351 + P338
  • 储存条件:
    请将贮藏器密封保存,并储存在阴凉干燥处。确保工作环境中具有良好通风或排气设施。

SDS

SDS:06db519bdf275c7cd13fbd223f3933fb
查看

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 2-(Tributylstannyl)thiophene
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 54663-78-4
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances



SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 3), H301
Specific target organ toxicity - repeated exposure (Category 1), H372
Acute toxicity, Dermal (Category 4), H312
Eye irritation (Category 2), H319
Skin irritation (Category 2), H315
Acute aquatic toxicity (Category 1), H400
Chronic aquatic toxicity (Category 1), H410
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
T Toxic R25, R48/23/25
Xn Harmful R21
Xi Irritant R36/38
N Dangerous for the R50/53
environment
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Danger
Hazard statement(s)
H301 Toxic if swallowed.
H312 Harmful in contact with skin.
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H372 Causes damage to organs through prolonged or repeated exposure.
H410 Very toxic to aquatic life with long lasting effects.
Precautionary statement(s)
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing.
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/
physician.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
P314 Get medical advice/ attention if you feel unwell.
P501 Dispose of contents/ container to an approved waste disposal plant.
Supplemental Hazard none
Statements
Other hazards - none

SECTION 3: Composition/information on ingredients
Substances
Formula : C16H30SSn
Molecular Weight : 373,18 g/mol
CAS-No. : 54663-78-4
Index-No. : 050-008-00-3
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
2-(Tributylstannyl)thiophene
CAS-No. 54663-78-4 Acute Tox. 3; STOT RE 1; <= 100 %
Index-No. 050-008-00-3 Acute Tox. 4; Eye Irrit. 2; Skin
Irrit. 2; Aquatic Acute 1;
Aquatic Chronic 1; H301,
H312, H315, H319, H372,
H410
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
2-(Tributylstannyl)thiophene
CAS-No. 54663-78-4 T, N, R21 - R25 - R36/38 - <= 100 %
Index-No. 050-008-00-3 R48/23/25 - R50/53
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, Sulphur oxides, Tin/tin oxides
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid breathing vapours, mist or gas. Ensure adequate ventilation.
Evacuate personnel to safe areas.
For personal protection see section 8.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into the
environment must be avoided.
Methods and materials for containment and cleaning up
Soak up with inert absorbent material and dispose of as hazardous waste. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist.
Normal measures for preventive fire protection.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Containers which are
opened must be carefully resealed and kept upright to prevent leakage.
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling
the product.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator
with multi-purpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup
to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air
respirator. Use respirators and components tested and approved under appropriate government
standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Discharge into
the environment must be avoided.

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: liquid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and 155 °C at 0,1 hPa - lit.
boiling range
g) Flash point 105 °C - closed cup
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density 1,175 g/cm3 at 25 °C
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
Causes damage to organs through prolonged or repeated exposure.
Aspiration hazard
no data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
Very toxic to aquatic life with long lasting effects.

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material.
Contaminated packaging
Dispose of as unused product.

SECTION 14: Transport information
UN number
ADR/RID: 2788 IMDG: 2788 IATA: 2788
UN proper shipping name
ADR/RID: ORGANOTIN COMPOUND, LIQUID, N.O.S. (2-(Tributylstannyl)thiophene)
IMDG: ORGANOTIN COMPOUND, LIQUID, N.O.S. (2-(Tributylstannyl)thiophene)
IATA: Organotin compound, liquid, n.o.s. (2-(Tributylstannyl)thiophene)
Transport hazard class(es)
ADR/RID: 6.1 IMDG: 6.1 IATA: 6.1
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: yes IMDG Marine pollutant: yes IATA: no
Special precautions for user
no data available

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox. Acute toxicity
Aquatic Acute Acute aquatic toxicity
Aquatic Chronic Chronic aquatic toxicity
Eye Irrit. Eye irritation
H301 Toxic if swallowed.
H312 Harmful in contact with skin.
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H372 Causes damage to organs through prolonged or repeated exposure.
H400 Very toxic to aquatic life.
H410 Very toxic to aquatic life with long lasting effects.
Full text of R-phrases referred to under sections 2 and 3
N Dangerous for the environment
T Toxic
R21 Harmful in contact with skin.
R25 Toxic if swallowed.
R36/38 Irritating to eyes and skin.
R48/23/25 Toxic: danger of serious damage to health by prolonged exposure through inhalation
and if swallowed.
R50/53 Very toxic to aquatic organisms, may cause long-term adverse effects in the aquatic
environment.
Further information
Copyright 2013 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.




反应信息

  • 作为反应物:
    描述:
    2-三丁基甲锡烷基噻吩 在 palladium diacetate 、 copper dichloride 作用下, 以 四氢呋喃 为溶剂, 反应 0.42h, 以99%的产率得到2,2'-联二噻吩
    参考文献:
    名称:
    通过Pd(II)催化剂和Cu(II)氧化剂温和有效地形成对称的联芳基
    摘要:
    本文描述了温和且有效的钯催化的由有机锡烷酸酯合成对称联芳基的方法。这种方法可以非常高的产量快速提供产品。
    DOI:
    10.1016/s0040-4039(01)01691-4
  • 作为产物:
    描述:
    三丁基氯化锡正丁基锂 作用下, 以 四氢呋喃正己烷 为溶剂, 反应 1.5h, 生成 2-三丁基甲锡烷基噻吩
    参考文献:
    名称:
    Acid secretion inhibitor
    摘要:
    本发明提供一种具有优越的抑制酸分泌作用并显示抗溃疡活性等的化合物。本发明提供一种由式(I)表示的化合物,其中R1是一种含氮的单环杂环基,可选择地与苯环或杂环缩合,该含氮的单环杂环基可选择地与苯环或杂环缩合,可选择地具有取代基,R2是可选择地取代的C6-14芳基,可选择地取代的噻吩基或可选择地取代的吡啶基,R3和R4分别是氢原子,或者R3和R4中的一个是氢原子,另一个是可选择地取代的较低烷基基团、酰基、卤原子、氰基或硝基,R5是烷基或其盐。
    公开号:
    US20070060623A1
  • 作为试剂:
    描述:
    4-碘苯甲醚N-甲基吡咯烷酮copper(l) iodide2-三丁基甲锡烷基噻吩 、 cesium fluoride 作用下, 反应 7.0h, 以10%的产率得到2-(4-甲氧苯基)噻吩
    参考文献:
    名称:
    在氯化钠存在下,铜和锰催化的有机锡与有机碘的交叉偶联。
    摘要:
    DOI:
    10.1021/jo970656j
点击查看最新优质反应信息

文献信息

  • [EN] IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH<br/>[FR] DÉRIVÉS IMIDAZOLE UTILES COMME INHIBITEURS DE LA FAAH
    申请人:MERCK & CO INC
    公开号:WO2009152025A1
    公开(公告)日:2009-12-17
    The present invention is directed to certain imidazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.
    本发明涉及某些咪唑衍生物,其可用作脂肪酰胺水解酶(FAAH)的抑制剂。该发明还涉及包含这些化合物作为活性成分的药物配方,以及这些化合物及其配方在治疗某些疾病中的使用,包括骨关节炎、类风湿性关节炎、糖尿病性神经病、带状疱疹后神经痛、骨骼肌肉疼痛和纤维肌痛,以及急性疼痛、偏头痛、睡眠障碍、阿尔茨海默病和帕金森病。
  • Synthesis of New Heteroaryl Substituted Morpholine Tagged Triazines and Evaluation of their Cytotoxic Activity
    作者:Sivaprasad Kasturi、Sujatha Surarapu、Srinivas Uppalanchi、Hasitha Shilpa Anantaraju、Shubham Dwivedi、Perumal Yogeeswari、Krishna S. Ethiraj、Jaya Shree Anireddy
    DOI:10.2174/1570180814666170605115335
    日期:2018.1.30
    Background: In the present study, new triazine derivatives 3, 4, 5, 6, 8 and 10 were synthesized starting from readily available cyanuric chloride 1 via nucleophilic displacement with morpholine followed by Suzuki or Stille coupling reactions and then the thermal displacement of chlorine atom with diverse substituted amines. Methods: All synthesized compounds were screened for their cytotoxic activity
    背景:在本研究中,新合成的三嗪衍生物3、4、5、6、8和10由容易获得的氰尿酰氯1经吗啉进行亲核取代,然后经Suzuki或Stille偶联反应,然后热取代氯原子而合成与各种取代的胺。 方法:筛选所有合成的化合物对HT-29,MDA-MB-231和HEK293细胞系的细胞毒活性。 结果与结论:化合物6a(HT50的IC50(µM):0.32,MDA-MB-231为2.92)和化合物8c(IC50(µM):HT-29为1.40,MDA-MB-231为1.60)。鉴定并与阿霉素和ZSTK474作参考标准进行比较。
  • Imidazoline derivatives as alpha-1A adrenoceptor ligands
    申请人:Bigham Eric Cleveland
    公开号:US06884801B1
    公开(公告)日:2005-04-26
    Compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof are disclosed. Such compounds are useful in the treatment of Alpha-1A mediated diseases or conditions such as urinary incontinence.
    化合物的化学式(I)或其药用可接受的盐或溶剂的复合物已被披露。这些化合物在治疗Alpha-1A介导的疾病或症状,如尿失禁方面是有用的。
  • Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
    申请人:Metabasis Therapeutics, Inc.
    公开号:US06756360B1
    公开(公告)日:2004-06-29
    Pharmaceutical compositions containing an FBPase inhibitor and an insulin sensitizer are provided as well as methods for treating diabetes and diseases responding to increased glycemic control, an improvement in insulin sensitivity, a reduction in insulin levels, or an enhancement of insulin secretion.
    提供含有FBPase抑制剂和胰岛素增敏剂的药物组合物,以及治疗糖尿病和对增加糖代谢控制、改善胰岛素敏感性、降低胰岛素水平或增强胰岛素分泌有响应的疾病的方法。
  • 腺苷受体拮抗剂
    申请人:厦门宝太生物科技股份有限公司
    公开号:CN112028891B
    公开(公告)日:2022-07-05
    本发明提供了一种式(I)化合物及其药物组合物。本发明的式(I)化合物可用作腺苷受体抑制剂,尤其是A2A和/或A2B抑制剂,例如可以用于预防或治疗与A2A和/或A2B活性或表达量相关的疾病。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
cnmr
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台

同类化合物

锡烷,[4-(2-乙基己基)-2-噻吩基]三甲基- 氯-噻吩-3-基汞 四噻吩-2-基锗烷 四(呋喃-2-基)锗 叠氮基(噻吩-2-基)汞 双(呋喃-3-基)汞 双(5-甲基呋喃-2-基)汞 二噻吩-2-基汞 二(呋喃-2-基)汞 三甲基锡烷(3-辛基-2-噻吩基)- 三甲基-(5-甲基呋喃-2-基)锡烷 三甲基-(1-甲基吡咯-2-基)锡烷 三乙氧基(噻吩-2-基)锗 三丁基锡硒酚 三丁基噻唑-5-锡 三丁基-(3-甲基-1,2-恶唑-5-基)锡烷 三丁基-(3,5-二甲基三唑-4-基)锡烷 三丁基-(2-甲基吡唑-3-基)锡烷 三丁基(4-辛基噻吩-2-基)锡 N -甲基- 2 -(三正丁基锡)-的1H -吡咯 5-甲基-2-(三丁基锡)呋喃 5-恶唑三丁基锡甲酸乙酯 5-噻吩-2-基-4,6,11-三氧杂-1-氮杂-5-锗杂双环[3.3.3]十一烷 4-异辛基噻吩-2-三丁基锡 4-三丁基锡烷基-3,5-二甲基异恶唑 4-(三丁基甲锡烷基)噻唑 3-甲基-2-(三丁基锡)噻吩 3-(三丁基锡烷基)噻吩 3-(三丁基锡)呋喃 2-噻吩基氯化汞 2-呋喃基氯化汞(II) 2-三丁基甲锡烷基噻唑 2-三丁基甲锡烷基噻吩 2-(三正丁基锡基)噁唑 2-(三丁基锡烷基)呋喃 2,5-双(三丁基锡)呋喃 2,5-二甲基锡呋喃 1-甲基-5-(三丁基锡烷基)-3-(三氟甲基)-1H-吡唑 1-甲基-4-(三丁基锡基)-1H-吡唑 (4-己基噻吩基)三丁基锡 (4-十二烷基-2-噻吩基)三甲基锡烷 (3-己基-2-噻吩基)三甲基锡烷 (3-十二烷基-2-噻吩基)三甲基锡烷 tributyl(4-methylthiophen-2-yl)stannane 2-methyl-3-(tri-n-butylstannyl)thiophene tris[2-(perfluorohexyl)ethyl](2'-furyl)tin poly[bis(2-thienyl)germanium] 1-methyl-5-tributylstannyl-4-trifluoromethylpyrazole tri-n-octyl(thiophen-2-yl)stannane (2-furyl)AlEt2(THF)